LAMP3 and melanoma: Elevated intratumoral levels of DC-LAMP+ DCs also constitute a robust positive prognostic value in multiple oncological settings, including non-small-cell lung carcinoma (NSCLC) [14, 21, 33], melanoma [34], renal cell carcinoma (RCC) [29], breast cancer [35] and colorectal carcinoma (CRC) [22].